Bengul Gursoy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bengul Gursoy has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Celal Satici
University of Health Sciences, Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, Department of Pulmonology, Istanbul, Turkey
2 shared publications - Elif Sargin Altunok
Departmen of Infectious Diseases and Clinical Microbiology, University of Health Sciences Kartal Dr. Lütfi Kırdar City Hospital, İstanbul, Türkiye
2 shared publications - Mustafa Asim Demirkol
Department of Allergy and Immunology, University of Health Sciences, Süreyyapaşa Training and Research Hospital, Istanbul, Türkiye
2 shared publications - Akaberk Börü
Department of Dermatology, Gaziosmanpasa Research and Training Hospital University of Health Sciences Istanbul Turkey
1 shared publication - Berna Demirok
Department of Infectious Diseases and Clinical Microbiology, Başakşehir Çam and Sakura City Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
1 shared publication - Berna Demirok
Department of Infectious Disease and Clinical Microbiology, Gaziosmanpasa Research and Training Hospital University of Health Sciences Istanbul Turkey
1 shared publication
Latest Publications
- Open Access
- 8 May 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5474-5480
Cytokine storm in severe COVID‐19 pneumonia
In this study, laboratorial parameters of hospitalized novel coronavirus (COVID‐19) patients, who were complicated with severe pneumonia, were compared with the findings of cytokine storm developing in macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH). Severe pneumonia occurred as a result of cytokine storm in some patients who needed intensive care unit (ICU), and it is aimed to determine the precursive parameters in this situation. Also in this study, the aim is to identify laboratory criteria that predict worsening disease and ICU intensification, as well as the development of cytokine storm. This article comprises a retrospective cohort study of patients admitted to a single institution with COVID‐19 pneumonia. This study includes 150 confirmed COVID‐19 patients with severe pneumonia. When they were considered as severe pneumonia patients, the clinic and laboratory parameters of this group are compared with H‐score criteria. Patients are divided into two subgroups; patients with worsened symptoms who were transferred into tertiary ICU, and patients with stable symptoms followed in the clinic. For the patients with confirmed COVID‐19 infection, after they become complicated with severe pneumonia, lymphocytopenia (55.3%), anemia (12.0%), thrombocytopenia (19.3%), hyperferritinemia (72.5%), hyperfibrinogenemia (63.7%) and elevated lactate dehydrogenase (LDH) (90.8%), aspartate aminotransaminase (AST) (31.3%), alanine aminotransaminase (ALT) (20.7%) are detected. There were no significant changes in other parameters. Blood parameters between the pre‐ICU period and the ICU period (in which their situation had been worsened and acute respiratory distress syndrome [ARDS] was developed) were also compared. In the latter group lymphocyte levels were found significantly reduced (p = 0.01), and LDH, highly sensitive troponin (hs‐troponin), procalcitonin, and triglyceride levels were significantly increased (p < 0.05). In addition, there was no change in hemoglobin, leukocyte, platelet, ferritin, and liver function test levels, including patients who developed ARDS, similar to the cytokine storm developed in MAS/sHLH. COVID‐19 pneumonia has similar findings as hyperinflammatory syndromes but does not seem to have typical features as in cytokine storm developed in MAS/sHLH. In the severe patient group who has started to develop ARDS signs, a decrease in lymphocyte level in addition to the elevated LDH, hs‐troponin, procalcitonin, and triglyceride levels can be a predictor in progression to ICU admission and could help in the planning of anti‐cytokine therapy.
- 8 May 2021
- Published by Wiley in Journal of Medical Virology
- Vol. 93 (9) , 5474-5480
Open AccessCytokine storm in severe COVID‐19 pneumonia
In this study, laboratorial parameters of hospitalized novel coronavirus (COVID‐19) patients, who were complicated with severe pneumonia, were compared with the findings of cytokine storm developing in macrophage activation syndrome (MAS)/secondary hemophagocytic lymphohistiocytosis (sHLH). Severe pneumonia occurred as a result of cytokine storm in some patients who needed intensive care unit (ICU), and it is aimed to determine the precursive parameters in this situation. Also in this study, the aim is to identify laboratory criteria that predict worsening disease and ICU intensification, as well as the development of cytokine storm. This article comprises a retrospective cohort study of patients admitted to a single institution with COVID‐19 pneumonia. This study includes 150 confirmed COVID‐19 patients with severe pneumonia. When they were considered as severe pneumonia patients, the clinic and laboratory parameters of this group are compared with H‐score criteria. Patients are divided into two subgroups; patients with worsened symptoms who were transferred into tertiary ICU, and patients with stable symptoms followed in the clinic. For the patients with confirmed COVID‐19 infection, after they become complicated with severe pneumonia, lymphocytopenia (55.3%), anemia (12.0%), thrombocytopenia (19.3%), hyperferritinemia (72.5%), hyperfibrinogenemia (63.7%) and elevated lactate dehydrogenase (LDH) (90.8%), aspartate aminotransaminase (AST) (31.3%), alanine aminotransaminase (ALT) (20.7%) are detected. There were no significant changes in other parameters. Blood parameters between the pre‐ICU period and the ICU period (in which their situation had been worsened and acute respiratory distress syndrome [ARDS] was developed) were also compared. In the latter group lymphocyte levels were found significantly reduced (p = 0.01), and LDH, highly sensitive troponin (hs‐troponin), procalcitonin, and triglyceride levels were significantly increased (p < 0.05). In addition, there was no change in hemoglobin, leukocyte, platelet, ferritin, and liver function test levels, including patients who developed ARDS, similar to the cytokine storm developed in MAS/sHLH. COVID‐19 pneumonia has similar findings as hyperinflammatory syndromes but does not seem to have typical features as in cytokine storm developed in MAS/sHLH. In the severe patient group who has started to develop ARDS signs, a decrease in lymphocyte level in addition to the elevated LDH, hs‐troponin, procalcitonin, and triglyceride levels can be a predictor in progression to ICU admission and could help in the planning of anti‐cytokine therapy.
- Open Access
- 1 September 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 98, 84-89
Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19
- 1 September 2020
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 98, 84-89
Open AccessPerformance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19